Purpose: To evaluate the diagnostic ability of diffusion‐weighted imaging (DWI) and dynamic contrast‐enhanced imaging (DCEI) in combination with T2‐weighted imaging (T2WI) for the detection of prostate cancer using 3 T magnetic resonance imaging (MRI) with a phased‐array body coil.Materials and Methods: Fifty‐three patients with elevated serum levels of prostate‐specific antigen (PSA) were evaluated by T2WI, DWI, and DCEI prior to needle biopsy. The obtained data from T2WI alone (protocol A), a combination of T2WI and DWI (protocol B), a combination T2WI and DCEI (protocol C), and a combination of T2WI plus DWI and DCEI (protocol D) were subjected to receiver operating characteristic (ROC) curve analysis.Results: The sensitivity, specificity, accuracy, and area under the ROC curve (Az) for region‐based analysis were: 61%, 91%, 84%, and 0.8415, respectively, in protocol A; 76%, 94%, 90%, and 0.8931, respectively, in protocol B; 77%, 93%, 89%, and 0.8655, respectively, in protocol C; and 81%, 96%, 92%, and 0.8968, respectively in protocol D. ROC analysis revealed significant differences between protocols A and B (P = 0.0008) and between protocols A and D (P = 0.0004).Conclusion: In patients with elevated PSA levels the combination of T2WI, DWI, DCEI using 3 T MRI may be a reasonable approach for the detection of prostate cancer. J. Magn. Reson. Imaging 2010;31:625–631.

OBJECTIVE. The purpose of this article is to review FDG PET/CT and MRI findings in a variety of benign and malignant tumors of the uterus and to become familiar with the wide variety of FDG PET/CT findings of this entity.CONCLUSION. Benign uterine tumors generally have mild FDG uptake, and leiomyoma rarely shows high uptake. Uterine malignant tumors generally have intense FDG uptake, whereas malignant uterine tumors that are small or that have low cellular density often show minimal uptake.

Purpose: To determine whether the apparent diffusion coefficient (ADC) obtained using a high b-value (2,000 s/mm2) is superior to that using a standard b-value (1,000 s/mm2) for discriminating malignant from normal peripheral tissue in the prostate. Methods: Twenty-six patients with biopsy-proven prostate cancer underwent 1.5T magnetic resonance (MR) imaging including single-shot, echo-planar diffusion-weighted imaging (DWI) with repetition time/echo time, 3500/88 ms; 4-mm slice thickness; 1-mm interslice gap; 144×128 matrix; field of view, 250×250 mm; number of excitations, 10; and b-values, 0, 1,000, and 2,000 s/mm2. For each patient, ADC values were obtained for malignant and normal tissue using b=1,000 and 2,000 in a monoexponential model. Signal-to-noise (SNR) and contrast-to-noise (CNR) ratios in DWI were also evaluated. Results: At b=1,000, the mean ADC (×10-3 mm2/s) for malignant tissue was 0.82±0.27 (range 0.43-1.29) and for normal tissue, 1.69±0.23 (1.31-2.18). At b=2000, the mean ADC for malignant tissue was 0.61±0.19 (0.30-0.94) and for normal tissue, 1.01±0.14 (0.73-1.35). Significant ADC overlap between the malignant and normal tissue was recognized at b=2000. As b-value increased, the mean SNR within malignant tissue decreased by 21.6%, and mean CNR decreased 17.3%. Conclusions: Under the same imaging conditions, measuring ADC using a high b-value (2,000 s/mm2) in a monoexponential model has little diagnostic advantage over using the standard b-value (1,000 s/mm2) in discriminating malignant from normal prostate tissue.